Search

Your search keyword '"Banerjee, Susana"' showing total 875 results
Start Over Author "Banerjee, Susana"
875 results on '"Banerjee, Susana"'

52. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Author

Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, Coyle, Christopher, Blagden, Sarah, Brenton, James D, Naik, Raj, Perren, Tim, Sundar, Sudha, Cook, Adrian D, Gopalakrishnan, Gosala S, Gabra, Hani, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Jones, Rachel, Williams, Sarah, Swart, Ann Marie, Stenning, Sally, Parmar, Mahesh, Kaplan, Richard, and Ledermann, Jonathan A

Published
2019
Full Text
View/download PDF

55. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Author

Fabbro, Michel, Moore, Kathleen N., Dørum, Anne, Tinker, Anna V., Mahner, Sven, Bover, Isabel, Banerjee, Susana, Tognon, Germana, Goffin, Frederic, Shapira-Frommer, Ronnie, Wenham, Robert M., Hellman, Kristina, Provencher, Diane, Harter, Philipp, Vázquez, Isabel Palacio, Follana, Philippe, Pineda, Mario J., Mirza, Mansoor R., Hazard, Sebastien J., and Matulonis, Ursula A.

Published
2019
Full Text
View/download PDF

58. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Author

Moore, Kathleen N., primary, Angelergues, Antoine, additional, Konecny, Gottfried E., additional, García, Yolanda, additional, Banerjee, Susana, additional, Lorusso, Domenica, additional, Lee, Jung-Yun, additional, Moroney, John W., additional, Colombo, Nicoletta, additional, Roszak, Andrzej, additional, Tromp, Jacqueline, additional, Myers, Tashanna, additional, Lee, Jeong-Won, additional, Beiner, Mario, additional, Cosgrove, Casey M., additional, Cibula, David, additional, Martin, Lainie P., additional, Sabatier, Renaud, additional, Buscema, Joseph, additional, Estévez-García, Purificación, additional, Coffman, Lan, additional, Nicum, Shibani, additional, Duska, Linda R., additional, Pignata, Sandro, additional, Gálvez, Fernando, additional, Wang, Yuemei, additional, Method, Michael, additional, Berkenblit, Anna, additional, Bello Roufai, Diana, additional, and Van Gorp, Toon, additional

Published
2023
Full Text
View/download PDF

59. Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, primary, Gilbert, Lucy, primary, Sabatier, Renaud, primary, Brown, Jubilee, primary, Ghamande, Sharad, primary, Mathews, Cara, primary, O'Malley, David M., primary, Kristeleit, Rebecca, primary, Boni, Valentina, primary, Gravina, Adriano, primary, Banerjee, Susana, primary, Miller, Rowan, primary, Pikiel, Joanna, primary, Mirza, Mansoor R., primary, Dewal, Ninad, primary, Antony, Grace, primary, Dong, Yuping, primary, Zografos, Eleftherios, primary, Veneris, Jennifer, primary, and Tinker, Anna V., primary

Published
2023
Full Text
View/download PDF

60. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Author

Drew, Yvette, primary, Kim, Jae-Weon, additional, Penson, Richard T., additional, O'Malley, David M., additional, Parkinson, Christine, additional, Roxburgh, Patricia, additional, Plummer, Ruth, additional, Im, Seock-Ah, additional, Imbimbo, Martina, additional, Ferguson, Michelle, additional, Rosengarten, Ora, additional, Steeghs, Neeltje, additional, Kim, Min Hwan, additional, Gal-Yam, Einav, additional, Tsoref, Daliah, additional, Kim, Jae-Hoon, additional, You, Benoit, additional, de Jonge, Maja, additional, Lalisang, Roy, additional, Gort, Eelke, additional, Bastian, Sara, additional, Meyer, Kassondra, additional, Feeney, Laura, additional, Baker, Nigel, additional, Ah-See, Mei-Lin, additional, Domchek, Susan M., additional, and Banerjee, Susana, additional

Published
2023
Full Text
View/download PDF

61. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Author

André, Thierry, primary, Berton, Dominique, additional, Curigliano, Giuseppe, additional, Sabatier, Renaud, additional, Tinker, Anna V., additional, Oaknin, Ana, additional, Ellard, Susan, additional, de Braud, Filippo, additional, Arkenau, Hendrik-Tobias, additional, Trigo, José, additional, Gravina, Adriano, additional, Kristeleit, Rebecca, additional, Moreno, Victor, additional, Abdeddaim, Cyril, additional, Vano, Yann-Alexandre, additional, Samouëlian, Vanessa, additional, Miller, Rowan, additional, Boni, Valentina, additional, Torres, Antonio Antón, additional, Gilbert, Lucy, additional, Brown, Jubilee, additional, Dewal, Ninad, additional, Dabrowski, Christine, additional, Antony, Grace, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Banerjee, Susana, additional

Published
2023
Full Text
View/download PDF

62. PO007LBA/#1550 Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study

Author

Lee, Jung-Yun, primary, Makker, Vicky, additional, Manso, Luis, additional, González-Martín, Antonio, additional, Ługowska, Iwona, additional, Lorusso, Domenica, additional, Banerjee, Susana, additional, Liao, John, additional, Lu, Chien-Hsing, additional, Prasongsook, Naiyarat, additional, Melichar, Bohuslav, additional, Chen, Kai, additional, Mcewen, Robert, additional, Michelini, Flavia, additional, Puvvada, Soham, additional, Meric-Bernstam, Funda, additional, and Oaknin, Ana, additional

Published
2023
Full Text
View/download PDF

63. PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy

Author

Grisham, Rachel, primary, Aghajanian, Carol, additional, Nieuwenhuysen, Els Van, additional, Rodrigues, Manuel, additional, Ring, Kari, additional, Santin, Alessandro, additional, Colombo, Nicoletta, additional, Prendergast, Emily, additional, Thaker, Premal, additional, Moore, Kathleen, additional, Salinas, Erin, additional, Ray-Coquard, Isabelle, additional, Chon, Hye Sook, additional, Rose, Peter, additional, Oaknin, Ana, additional, Clamp, Andrew, additional, Gandhi, Mitul, additional, Monk, Bradley, additional, Holloway, Robert, additional, Gorp, Toon Van, additional, Fabbro, Michel, additional, Gennigens, Christine, additional, Wojtynek, Nicholas, additional, Lustgarten, Stephanie, additional, and Banerjee, Susana, additional

Published
2023
Full Text
View/download PDF

65. The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer

Author

Fagan, Paula J, primary, Gomes, Nana, additional, Heath, Owen M, additional, Chandrasekaran, Dhivya, additional, Yao, Shih-Ern, additional, Satchwell, Laura, additional, George, Angela, additional, Banerjee, Susana, additional, Sohaib, Aslam, additional, Barton, Desmond P, additional, Nobbenhuis, Marielle, additional, Ind, Thomas, additional, and Butler, John, additional

Published
2023
Full Text
View/download PDF

66. Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, primary, Banerjee, Susana, primary, Drill, Esther, primary, Kalbacher, Elsa, primary, Mirza, Mansoor Raza, primary, Romero, Ignacio, primary, Vuylsteke, Peter, primary, Coleman, Robert L., primary, Hilpert, Felix, primary, Oza, Amit M., primary, Westermann, Anneke, primary, Oehler, Martin K., primary, Pignata, Sandro, primary, Aghajanian, Carol, primary, Colombo, Nicoletta, primary, Cibula, David, primary, Moore, Kathleen N., primary, del Campo, Josep M., primary, Berger, Regina, primary, Marth, Christian, primary, Sehouli, Jalid, primary, O'Malley, David M., primary, Churruca, Cristina, primary, Kristensen, Gunnar, primary, Clamp, Andrew, primary, Farley, John, primary, Iyer, Gopa, primary, Ray-Coquard, Isabelle, primary, and Monk, Bradley J., primary

Published
2023
Full Text
View/download PDF

67. Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, primary, Banerjee, Susana, primary, Drill, Esther, primary, Kalbacher, Elsa, primary, Mirza, Mansoor Raza, primary, Romero, Ignacio, primary, Vuylsteke, Peter, primary, Coleman, Robert L., primary, Hilpert, Felix, primary, Oza, Amit M., primary, Westermann, Anneke, primary, Oehler, Martin K., primary, Pignata, Sandro, primary, Aghajanian, Carol, primary, Colombo, Nicoletta, primary, Cibula, David, primary, Moore, Kathleen N., primary, del Campo, Josep M., primary, Berger, Regina, primary, Marth, Christian, primary, Sehouli, Jalid, primary, O'Malley, David M., primary, Churruca, Cristina, primary, Kristensen, Gunnar, primary, Clamp, Andrew, primary, Farley, John, primary, Iyer, Gopa, primary, Ray-Coquard, Isabelle, primary, and Monk, Bradley J., primary

Published
2023
Full Text
View/download PDF

68. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Author

Clamp, Andrew R, Lorusso, Domenica, Oza, Amit M, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W, Gancedo, Margarita Amenedo, Fong, Peter C, Goh, Jeffrey C, OʼMalley, David M, Armstrong, Deborah K, Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M, Cameron, Terri, Goble, Sandra, Coleman, Robert L, and Ledermann, Jonathan A

Published
2021
Full Text
View/download PDF

70. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Author

Oza, Amit M, Matulonis, Ursula A, Malander, Susanne, Hudgens, Stacie, Sehouli, Jalid, del Campo, Josep M, Berton-Rigaud, Dominique, Banerjee, Susana, Scambia, Giovanni, Berek, Jonathan S, Lund, Bente, Tinker, Anna V, Hilpert, Felix, Vázquez, Isabel Palacio, D'Hondt, Véronique, Benigno, Benedict, Provencher, Diane, Buscema, Joseph, Agarwal, Shefali, and Mirza, Mansoor R

Published
2018
Full Text
View/download PDF

73. Global cancer control: responding to the growing burden, rising costs and inequalities in access

Author

Prager, Gerald W., Braga, Sofia, Bystricky, Branislav, Qvortrup, Camilla, Criscitiello, Carmen, Esin, Ece, Sonke, Gabe S., Martínez, GuillemArgilés, Frenel, Jean-Sebastian, Karamouzis, Michalis, Strijbos, Michiel, Yazici, Ozan, Bossi, Paolo, Banerjee, Susana, Troiani, Teresa, Eniu, Alexandru, Ciardiello, Fortunato, Tabernero, Josep, Zielinski, Christoph C., Casali, Paolo G., Cardoso, Fatima, Douillard, Jean-Yves, Jezdic, Svetlana, McGregor, Keith, Bricalli, Gracemarie, Vyas, Malvika, and Ilbawi, André

Published
2018
Full Text
View/download PDF

77. The interaction between vascular endothelial growth factor and oestrogen signalling in breast cancer

Author

Banerjee, Susana

Subjects
616.994
Abstract

Therapies targeting the oestrogenic stimulation of tumour growth have been a major success in reducing mortality from oestrogen receptor (ER)-positive breast cancer. However, resistance remains a major clinical problem. Various cellular signalling pathways, including the pro-angiogenic Vascular Endothelial Growth Factor (VEGF) pathway, have been implicated in the mechanism of therapeutic resistance. The aim of this project was to investigate the relationship between oestrogen- and VEGF-mediated signalling in breast cancer. The clinical relevance of the interaction between the ER and VEGF pathways was evaluated in two clinical studies: (i) Circulating VEGF and sVEGFR-1 levels were measured both before and after administration of endocrine therapy in women with primary breast cancer. The results provided evidence for possible cross-talk between ER- and VEGF-signalling. However, the aromatase inhibitor (AI) anastrozole and the ER-antagonist tamoxifen had differential effects on VEGF and sVEGFR-1. (ii) The expression of VEGF, VEGFR-2 and pVEGFR-2 and assoications with ER, PgR, pp38 and HER2 were investigated in paired samples of breast cancers before and after relapse following tamoxifen treatment. Positive correlations between ER and PgR with VEGF were noted in the relapse specimens which were not present in the primary cancers, providing support for an interaction between the ER- and VEGF-signalling pathways that may be relevant to endocrine therapy resistance. The role of ER in the regulation of VEGF expression was investigated in cell lines modelling resistance to tamoxifen and Als. Oestradiol(bound)-ER increased VEGF promoter activity and VEGF secretion and HER2 knockdown reduced VEGF secretion. This suggested that ER regulates VEGF in resistance and showed that an imperfect oestrogen response element (ERE) dependent mechanism is likely to be involved. The possibility of targeting ER- and VEGF- pathways together was investigated, initially by combining an Al with a VEGFR inhibitor (PTK787). Unexpectedly, this inhibitor was shown to directly inhibit aromatase activity in vitro. PTK787 decreased the number of vessels, cell turnover index, uterine weight, PgR and TFF1 in vivo suggesting that dual targeting of both angiogenic and endocrine signalling in a single agent is possible and may be worth exploring further. This series of studies has provided new insight into the significance of VEGF in ER-positive breast cancer, particularly that which has progressed to endocrine resistance. In addition, the ability of a single small molecule inhibitor to inhibit two distinct biological pathways may allow the rational development of agents designed to inhibit cross class targets.

Published
2009

79. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Author

Banerjee, Susana N, primary, Ring, Kari L, additional, Niewenhuysen, Els Van, additional, Fabbro, Michel, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Colombo, Nicoletta, additional, Santin, Alessandro D, additional, Clamp, Andrew R, additional, Moore, Kathleen N, additional, Rose, Peter G, additional, David M, O’Malley, additional, Chon, Hye Sook, additional, Salinas, Erin A, additional, Prendergast, Emily N, additional, Lustgarten, Stephanie, additional, Rodrigues, Manuel, additional, Gennigens, Christine, additional, Monk, Bradley J, additional, and Grisham, Rachel N, additional

Published
2023
Full Text
View/download PDF

81. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Author

Vergote, Ignace, primary, Van Nieuwenhuysen, Els, additional, O'Cearbhaill, Roisin E., additional, Westermann, Anneke, additional, Lorusso, Domenica, additional, Ghamande, Sharad, additional, Collins, Dearbhaile C., additional, Banerjee, Susana, additional, Mathews, Cara A., additional, Gennigens, Christine, additional, Cibula, David, additional, Tewari, Krishnansu S., additional, Madsen, Kristine, additional, Köse, Fatih, additional, Jackson, Amanda L., additional, Boere, Ingrid A., additional, Scambia, Giovanni, additional, Randall, Leslie M., additional, Sadozye, Azmat, additional, Baurain, Jean-François, additional, Gort, Eelke, additional, Zikán, Michal, additional, Denys, Hannelore G., additional, Ottevanger, Nelleke, additional, Forget, Frédéric, additional, Mondrup Andreassen, Camilla, additional, Eaton, Lamar, additional, Chisamore, Michael J., additional, Viana Nicacio, Leonardo, additional, Soumaoro, Ibrahima, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

82. Low-grade serous ovarian cancer: expert consensus report on the state of the science

Author

Grisham, Rachel N, primary, Slomovitz, Brian M, additional, Andrews, Nicole, additional, Banerjee, Susana, additional, Brown, Jubilee, additional, Carey, Mark S, additional, Chui, Herman, additional, Coleman, Robert L, additional, Fader, Amanda N, additional, Gaillard, Stephanie, additional, Gourley, Charlie, additional, Sood, Anil K, additional, Monk, Bradley J, additional, Moore, Kathleen N, additional, Ray-Coquard, Isabelle, additional, Shih, Ie-Ming, additional, Westin, Shannon N, additional, Wong, Kwong-Kwok, additional, and Gershenson, David M, additional

Published
2023
Full Text
View/download PDF

83. Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Author

Grisham, Rachel N., primary, Vergote, Ignace, additional, Banerjee, Susana, additional, Drill, Esther, additional, Kalbacher, Elsa, additional, Mirza, Mansoor Raza, additional, Romero, Ignacio, additional, Vuylsteke, Peter, additional, Coleman, Robert L., additional, Hilpert, Felix, additional, Oza, Amit M., additional, Westermann, Anneke, additional, Oehler, Martin K., additional, Pignata, Sandro, additional, Aghajanian, Carol, additional, Colombo, Nicoletta, additional, Cibula, David, additional, Moore, Kathleen N., additional, del Campo, Josep M., additional, Berger, Regina, additional, Marth, Christian, additional, Sehouli, Jalid, additional, O'Malley, David M., additional, Churruca, Cristina, additional, Kristensen, Gunnar, additional, Clamp, Andrew, additional, Farley, John, additional, Iyer, Gopa, additional, Ray-Coquard, Isabelle, additional, and Monk, Bradley J., additional

Published
2023
Full Text
View/download PDF

84. Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, primary, Gilbert, Lucy, primary, Sabatier, Renaud, primary, Brown, Jubilee, primary, Ghamande, Sharad, primary, Mathews, Cara, primary, O'Malley, David M., primary, Kristeleit, Rebecca, primary, Boni, Valentina, primary, Gravina, Adriano, primary, Banerjee, Susana, primary, Miller, Rowan, primary, Pikiel, Joanna, primary, Mirza, Mansoor R., primary, Dewal, Ninad, primary, Antony, Grace, primary, Dong, Yuping, primary, Zografos, Eleftherios, primary, Veneris, Jennifer, primary, and Tinker, Anna V., primary

Published
2023
Full Text
View/download PDF

85. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Author

Oaknin, Ana, primary, Pothuri, Bhavana, additional, Gilbert, Lucy, additional, Sabatier, Renaud, additional, Brown, Jubilee, additional, Ghamande, Sharad, additional, Mathews, Cara, additional, O'Malley, David M., additional, Kristeleit, Rebecca, additional, Boni, Valentina, additional, Gravina, Adriano, additional, Banerjee, Susana, additional, Miller, Rowan, additional, Pikiel, Joanna, additional, Mirza, Mansoor R., additional, Dewal, Ninad, additional, Antony, Grace, additional, Dong, Yuping, additional, Zografos, Eleftherios, additional, Veneris, Jennifer, additional, and Tinker, Anna V., additional

Published
2023
Full Text
View/download PDF

86. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, de la Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Kim, Jae Hoon, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez de Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Kim, Jae Weon, Hegg, Roberto, Vergote, Ignace, Pujade-Lauraine, Eric, Ledermann, Jonathan A, Gebski, Val, Penson, Richard T, Oza, Amit M, Poveda, Andrés, Fujiwara, Keiichi, Liu, Joyce, Lowe, Elizabeth S, and Bloomfield, Ralph

Published
2017
Full Text
View/download PDF

87. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients

Author

Capoluongo, Ettore, Ellison, Gillian, López-Guerrero, José Antonio, Penault-Llorca, Frederique, Ligtenberg, Marjolijn J.L., Banerjee, Susana, Singer, Christian, Friedman, Eitan, Markiefka, Birgid, Schirmacher, Peter, Büttner, Reinhard, van Asperen, Christi J., Ray-Coquard, Isabelle, Endris, Volker, Kamel-Reid, Suzanne, Percival, Natalie, Bryce, Jane, Röthlisberger, Benno, Soong, Richie, and de Castro, David Gonzalez

Published
2017
Full Text
View/download PDF

90. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

Author

Meric-Bernstam, Funda, Makker, Vicky, Oaknin, Ana, Oh, Do-Youn, Banerjee, Susana, González-Martín, Antonio, Jung, Kyung Hae, Ługowska, Iwona, Manso, Luis, Manzano, Aránzazu, Melichar, Bohuslav, Siena, Salvatore, Stroyakovskiy, Daniil, Fielding, Anitra, Ma, Yan, Puvvada, Soham, Shire, Norah, and Lee, Jung-Yun

Published
2024
Full Text
View/download PDF

93. Is risk reduction mastectomy safe after ovarian cancer in women with GBRCA variant

Author

Ain, Quratul, primary, Swarnkar, Parinita, additional, Krupa, Katherine, additional, Barry, Peter A., additional, Tasoulis, Marios, additional, Wiggins, Jennifer, additional, McVeigh, Terri, additional, Kemp, Zoe, additional, George, Angela, additional, Khan, Aadil, additional, Gui, Gerald, additional, Banerjee, Susana, additional, Rusby, Jennifer, additional, and O'Connell, Rachel, additional

Published
2023
Full Text
View/download PDF

94. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma

Author

Banerjee, Susana, primary, Giannone, Gaia, additional, Clamp, Andrew R., additional, Ennis, Darren P., additional, Glasspool, Rosalind M., additional, Herbertson, Rebecca, additional, Krell, Jonathan, additional, Riisnaes, Ruth, additional, Mirza, Hasan B., additional, Cheng, Zhao, additional, McDermott, Jacqueline, additional, Green, Clare, additional, Kristeleit, Rebecca S., additional, George, Angela, additional, Gourley, Charlie, additional, Lewsley, Liz-Anne, additional, Rai, Debbie, additional, Banerji, Udai, additional, Hinsley, Samantha, additional, and McNeish, Iain A., additional

Published
2023
Full Text
View/download PDF

95. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Author

Morgan, Robert D, primary, Clamp, Andrew R, additional, Barnes, Bethany M, additional, Timms, Kirsten, additional, Schlecht, Helene, additional, Yarram-Smith, Laura, additional, Wallis, Yvonne, additional, Valganon-Petrizan, Mikel, additional, MacMahon, Suzanne, additional, White, Rhian, additional, Morgan, Sian, additional, McKenna, Sarah, additional, Hudson, Emma, additional, Tookman, Laura, additional, George, Angela, additional, Manchanda, Ranjit, additional, Sundar, Sudha S, additional, Nicum, Shibani, additional, Brenton, James D, additional, Kristeleit, Rebecca S, additional, Banerjee, Susana, additional, McNeish, Iain A, additional, Ledermann, Jonathan A, additional, Taylor, Stephen S, additional, Evans, D Gareth R, additional, and Jayson, Gordon C, additional

Published
2023
Full Text
View/download PDF

96. Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Author

Banerjee, Susana, primary, Michalarea, Vasiliki, primary, Ang, Joo Ern, primary, Ingles Garces, Alvaro, primary, Biondo, Andrea, primary, Funingana, Ionut-Gabriel, primary, Little, Martin, primary, Ruddle, Ruth, primary, Raynaud, Florence, primary, Riisnaes, Ruth, primary, Gurel, Bora, primary, Chua, Sue, primary, Tunariu, Nina, primary, Porter, Joanna C., primary, Prout, Toby, primary, Parmar, Mona, primary, Zachariou, Anna, primary, Turner, Alison, primary, Jenkins, Ben, primary, McIntosh, Stuart, primary, Ainscow, Ed, primary, Minchom, Anna, primary, Lopez, Juanita, primary, de Bono, Johann, primary, Jones, Robert, primary, Hall, Emma, primary, Cook, Natalie, primary, Basu, Bristi, primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

97. Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Author

Banerjee, Susana, primary, Michalarea, Vasiliki, primary, Ang, Joo Ern, primary, Ingles Garces, Alvaro, primary, Biondo, Andrea, primary, Funingana, Ionut-Gabriel, primary, Little, Martin, primary, Ruddle, Ruth, primary, Raynaud, Florence, primary, Riisnaes, Ruth, primary, Gurel, Bora, primary, Chua, Sue, primary, Tunariu, Nina, primary, Porter, Joanna C., primary, Prout, Toby, primary, Parmar, Mona, primary, Zachariou, Anna, primary, Turner, Alison, primary, Jenkins, Ben, primary, McIntosh, Stuart, primary, Ainscow, Ed, primary, Minchom, Anna, primary, Lopez, Juanita, primary, de Bono, Johann, primary, Jones, Robert, primary, Hall, Emma, primary, Cook, Natalie, primary, Basu, Bristi, primary, and Banerji, Udai, primary

Published
2023
Full Text
View/download PDF

98. Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer:Results from the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Author

Vergote, Ignace, Van Nieuwenhuysen, Els, O'Cearbhaill, Roisin E., Westermann, Anneke, Lorusso, Domenica, Ghamande, Sharad, Collins, Dearbhaile C., Banerjee, Susana, Mathews, Cara A., Gennigens, Christine, Cibula, David, Tewari, Krishnansu S., Madsen, Kristine, Köse, Fatih, Jackson, Amanda L., Boere, Ingrid A., Scambia, Giovanni, Randall, Leslie M., Sadozye, Azmat, Baurain, Jean François, Gort, Eelke, Zikán, Michal, Denys, Hannelore G., Ottevanger, Nelleke, Forget, Frédéric, Mondrup Andreassen, Camilla, Eaton, Lamar, Chisamore, Michael J., Viana Nicacio, Leonardo, Soumaoro, Ibrahima, Monk, Bradley J., Vergote, Ignace, Van Nieuwenhuysen, Els, O'Cearbhaill, Roisin E., Westermann, Anneke, Lorusso, Domenica, Ghamande, Sharad, Collins, Dearbhaile C., Banerjee, Susana, Mathews, Cara A., Gennigens, Christine, Cibula, David, Tewari, Krishnansu S., Madsen, Kristine, Köse, Fatih, Jackson, Amanda L., Boere, Ingrid A., Scambia, Giovanni, Randall, Leslie M., Sadozye, Azmat, Baurain, Jean François, Gort, Eelke, Zikán, Michal, Denys, Hannelore G., Ottevanger, Nelleke, Forget, Frédéric, Mondrup Andreassen, Camilla, Eaton, Lamar, Chisamore, Michael J., Viana Nicacio, Leonardo, Soumaoro, Ibrahima, and Monk, Bradley J.

Abstract

PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).CONCLUSION TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.

Published
2023

99. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Author

Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G, Gourley, C, Oza, A, González-Martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E, Ah-See, M, Moore, K, DiSilvestro, Paul, Banerjee, Susana, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S, Gourley, Charlie, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William, Mathews, Cara, Liu, Joyce, McNamara, John, Lowe, Elizabeth S, Ah-See, Mei-Lin, Moore, Kathleen N, Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G, Gourley, C, Oza, A, González-Martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E, Ah-See, M, Moore, K, DiSilvestro, Paul, Banerjee, Susana, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S, Gourley, Charlie, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William, Mathews, Cara, Liu, Joyce, McNamara, John, Lowe, Elizabeth S, Ah-See, Mei-Lin, and Moore, Kathleen N

Abstract

PURPOSEIn SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutation. We report overall survival (OS) after a 7-year follow-up, a clinically relevant time point and the longest follow-up for any poly(ADP-ribose) polymerase inhibitor in the first-line setting.METHODSThis double-blind phase III trial randomly assigned patients with newly diagnosed advanced ovarian cancer and a BRCA mutation in clinical response to platinum-based chemotherapy to maintenance olaparib (n = 260) or placebo (n = 131) for up to 2 years. A prespecified descriptive analysis of OS, a secondary end point, was conducted after a 7-year follow-up.RESULTSThe median duration of treatment was 24.6 months with olaparib and 13.9 months with placebo, and the median follow-up was 88.9 and 87.4 months, respectively. The hazard ratio for OS was 0.55 (95% CI, 0.40 to 0.76; P =.0004 [P <.0001 required to declare statistical significance]). At 7 years, 67.0% of olaparib patients versus 46.5% of placebo patients were alive, and 45.3% versus 20.6%, respectively, were alive and had not received a first subsequent treatment (Kaplan-Meier estimates). The incidence of myelodysplastic syndrome and acute myeloid leukemia remained low, and new primary malignancies remained balanced between treatment groups.CONCLUSIONResults indicate a clinically meaningful, albeit not statistically significant according to prespecified criteria, improvement in OS with maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation and support the use of maintenance olaparib to achieve long-term remission in this setting; the potential for cure may also be enhanced. No new safety signals were observed during long-term follow-up.

Published
2023

100. Young oncologists’ perspective on the role and future of the clinician-scientist in oncology

Author

Lim, Kok Haw Jonathan, Westphalen, Christoph Benedikt, Berghoff, Anna Sophie, Cardone, Claudia, Connolly, Elizabeth, Güven, Deniz Can, Kfoury, Maria, Kocakavuk, Emre, Mandó, Pablo, Mariamidze, Elene, Matikas, Alexios, Moutafi, Myrto MK, Oing, Christoph, Pihlak, R., Punie, Kevin, Sánchez-Bayona, Rodrigo, Sobczuk, Paweł, Starzer, Angelika Martina, Tecic Vuger, Ana, Zhu, Hongcheng, Cruz-Ordinario, Mel Valerie M.V.B., Altuna, Sara Cecilia, Canário, Rita, Vuylsteke, Peter, Banerjee, Susana, de Azambuja, Evandro, Cervantes, Andrés, Lambertini, Matteo Md Phd M., Mateo, Joaquin, Amaral, Teresa, Lim, Kok Haw Jonathan, Westphalen, Christoph Benedikt, Berghoff, Anna Sophie, Cardone, Claudia, Connolly, Elizabeth, Güven, Deniz Can, Kfoury, Maria, Kocakavuk, Emre, Mandó, Pablo, Mariamidze, Elene, Matikas, Alexios, Moutafi, Myrto MK, Oing, Christoph, Pihlak, R., Punie, Kevin, Sánchez-Bayona, Rodrigo, Sobczuk, Paweł, Starzer, Angelika Martina, Tecic Vuger, Ana, Zhu, Hongcheng, Cruz-Ordinario, Mel Valerie M.V.B., Altuna, Sara Cecilia, Canário, Rita, Vuylsteke, Peter, Banerjee, Susana, de Azambuja, Evandro, Cervantes, Andrés, Lambertini, Matteo Md Phd M., Mateo, Joaquin, and Amaral, Teresa

Abstract

SCOPUS: ed.j, info:eu-repo/semantics/published

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results